Anxiolytic Properties of the TRPV1 Receptor Antagonist in a Dark/Light Chamber Test on ICR Mice
https://doi.org/10.33647/2713-0428-20-3E-229-232
Abstract
TRPV1, a key mediator of nociceptive signaling, is widely distributed in various tissues and cells, including the central nervous system. The regulatory activity of TRPV1 affects neural desensitization, pain transmission, and neurotransmitter systems. The use of the beneficial peptide APHC3 as a selective antagonist of TRPV1 is a method for studying the blocking of this channel at the level of anxiety and is a response to stress in mice. The findings improve our understanding of the influence of TRPV1 on the moderation of emotional states. This study has important implications for understanding the effects of TRPV1 on stress states in ICR mice and may also contribute to medical and biomedical research.
Supporting agencies: this work was funded from the budget of the Laboratory of Biological Tests of the Branch of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences.
About the Authors
A. Yu. Fedotova
Branch of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences;
Pushchino Branch of the Russian Biotechnological University
Russian Federation
Russian Federation
Anastasia Yu. Fedotova
142290, Moscow Region, Pushchino, Nauki Ave., 6;
142290, Moscow Region, Pushchino, Nauki Ave., 3
V. M. Pavlov
Branch of the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences;
Pushchino Branch of the Russian Biotechnological University
Russian Federation
Russian Federation
Vladimir M. Pavlov
142290, Moscow Region, Pushchino, Nauki Ave., 6;
142290, Moscow Region, Pushchino, Nauki Ave., 3
References
1. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv [Guidelines for conducting preclinical studies of medicines]. Ed. by A.N. Mironov. Moscow: Grif I K. Publ., 2012. (In Russian).
2. Aghazadeh T.M., Baraldi P.G., Baraldi S., Gessi S., Merighi S., Borea P.A. Medicinal chemistry, pharmacology, and clinical implications of TRPV1 receptor antagonists. Med. Res. Rev. 2017;37(4):936–983. DOI: 10.1002/med.21427
3. Aguiar D.C., Terzian A.L., Guimarães F.S., Moreira F.A. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl.). 2009;205(2):217–225. DOI: 10.1007/s00213-009-1532-5
4. Andreev Ya.A., Kozlov S.A., Korolkova Y.V., Dyachenko I.A., Bondarenko D.A., Skobtsov D.I., Murashev A.N., Kotova P.D., Rogachevskaja O.A., Kabanova N.V., Kolesnikov S.S., Grishin E.V. Polypeptide modulators of TRPV1 produce analgesia without hyperthermia. Mar. Drugs. 2013;11(12):5100–5115. DOI: 10.3390/md11125100
5. Bevan S., Quallo T., Andersson D.A. TRPV1. Handb. Exp. Pharmacol. 2014;222:207–245. DOI: 10.1007/978-3-642-54215-2_9
6. Esipov R.S., Makarov D.A., Stepanenko V.N., Kostromina M.A., Muravyova T.I., Andreev Y.A., Dyachenko I.A., Kozlov S.A., Grishin E.V. Pilot production of the recombinant peptide toxin of Heteractis crispa as a potential analgesic by intein-mediated technology. Protein Expr. Purif. 2018;145:71–76. DOI: 10.1016/j.pep.2017.12.011
7. Katz B., Zaguri R., Edvardson S., Maayan C., Elpeleg O., Lev S., Davidson E., Peters M., KfirErenfeld S., Berger E., Ghazalin S., Binshtok A.M., Minke B. Nociception and pain in humans lacking a functional TRPV1 channel. J. Clin. Invest. 2023;133(3):e153558. DOI: 10.1172/JCI153558
8. Kolesova Y.S., Stroylova Y.Y., Maleeva E.E., Moysenovich A.M., Pozdyshev D.V., Muronetz V.I., Andreev Y.A. Modulation of TRPV1 and TRPA1 Channels function by sea anemones’ peptides enhances the viability of SH-SY5Y cell model of Parkinson’s disease. Int. J. Mol. Sci. 2024;25(1):368. DOI: 10.3390/ijms25010368
9. Kozlov S.A., Andreev Ia.A., Murashev A.N., Skobtsov D.I., D'iachenko I.A., Grishin E.V. New polypeptide components from the Heteractis crispa sea anemone with analgesic activity. Bioorg. Chem. 2009;35(6):711–719. DOI: 10.1134/s1068162009060065
10. Logashina Yu.A., Palikova Y.A., Palikov V.A., Kazakov V.A., Smolskaya S.V., Dyachenko I.A., Tarasova N.V., Andreev Y.A. Anti-inflammatory and analgesic effects of TRPV1 polypeptide modulator APHC3 in models of osteo- and rheumatoid arthritis. Mar. Drugs. 2021;19(1):39. DOI: 10.3390/md19010039
Review
For citations:
Fedotova A.Yu., Pavlov V.M. Anxiolytic Properties of the TRPV1 Receptor Antagonist in a Dark/Light Chamber Test on ICR Mice. Journal Biomed. 2024;20(3E):229-232. (In Russ.) https://doi.org/10.33647/2713-0428-20-3E-229-232
Views:
98
Email this article 
